Yongjun Yu
Overview
Explore the profile of Yongjun Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fan L, Zheng M, Zhou X, Yu Y, Ning Y, Fu W, et al.
J Transl Med
. 2023 Oct;
21(1):719.
PMID: 37833712
Background: Polyploid giant cancer cells (PGCCs), a specific type of cancer stem cells (CSCs), can be induced by hypoxic microenvironments, chemical reagents, radiotherapy, and Chinese herbal medicine. Moreover, PGCCs can...
12.
Huang P, Zhou X, Zheng M, Yu Y, Jin G, Zhang S
Front Immunol
. 2023 Sep;
14:1263537.
PMID: 37767092
Introduction: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of distant metastasis, an extremely poor prognosis, and a high risk of death....
13.
He X, Yu Y, Zhang X, Gao C, Wang H, Liu C
Cancer Genomics Proteomics
. 2023 Aug;
20(5):476-486.
PMID: 37643778
Background/aim: The immunogenic cell death (ICD) pathway plays a crucial prognostic role in lung adenocarcinoma (LUAD) therapy. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an upstream...
14.
Yang X, Zheng M, Ning Y, Sun J, Yu Y, Zhang S
J Transl Med
. 2023 Jul;
21(1):456.
PMID: 37434173
Background: Epithelial ovarian cancer is the leading cause of death from gynecologic cancer, in which serous ovarian carcinoma (SOC) is the most common histological subtype. Although PARP inhibitors (PARPi) and...
15.
Zhang J, Ma C, Yu Y, Liu C, Fang L, Rao H
J Biol Chem
. 2023 Jul;
299(8):104994.
PMID: 37392851
Proteolysis-targeting chimera (PROTAC) that specifically targets harmful proteins for destruction by hijacking the ubiquitin-proteasome system is emerging as a potent anticancer strategy. How to efficiently modulate the target degradation remains...
16.
Yu Y, Li Y, Xu C, Zhang W
Indian J Cancer
. 2023 Mar;
61(2):317-323.
PMID: 36861718
Background: This study was designed to investigate the efficacy and safety of apatinib monotherapy in the treatment of elderly patients with advanced colorectal cancer (CRC) who have progressed on the...
17.
Cai H, Du R, Song J, Wang Z, Wang X, Yu Y, et al.
J ECT
. 2023 Feb;
39(3):166-172.
PMID: 36800536
Objective: Few studies on electroconvulsive therapy (ECT) investigate efficacy and safety on depressive adolescents with strong suicidal ideation. Our study examined adolescents (aged 13-18 years) with major depressive disorder to...
18.
Xu C, Cong J, Liu T, Jiao C, Li M, Yu Y, et al.
Clin Res Hepatol Gastroenterol
. 2022 Jul;
46(9):101998.
PMID: 35863732
Background: This study aimed to evaluate the colonic motility of slow transit constipation (STC) patients using high-resolution colonic manometry (HRCM) and classify the patients' subtypes to instruct treatment based on...
19.
Cucolo L, Chen Q, Qiu J, Yu Y, Klapholz M, Budinich K, et al.
Immunity
. 2022 Apr;
55(4):671-685.e10.
PMID: 35417675
Interferon-gamma (IFN-γ) has pleiotropic effects on cancer immune checkpoint blockade (ICB), including roles in ICB resistance. We analyzed gene expression in ICB-sensitive versus ICB-resistant tumor cells and identified a strong...
20.
Bian Z, Li H, Liu Y, Cao Y, Kang Y, Yu Y, et al.
Neuropsychiatr Dis Treat
. 2021 Sep;
17:2987-2994.
PMID: 34588778
Background: The occurrence of depression was related with a state of mild hypoxia for a long time. Hypoxia-inducible factor-2α (HIF-2α) modulates the process from acute to chronic hypoxia, consequently regulating...